Literature DB >> 33498525

Targeting DNA Repair and Chromatin Crosstalk in Cancer Therapy.

Danielle P Johnson1, Mahesh B Chandrasekharan1, Marie Dutreix2, Srividya Bhaskara1.   

Abstract

Aberrant DNA repair pathways that underlie developmental diseases and cancers are potential targets for therapeutic intervention. Targeting DNA repair signal effectors, modulators and checkpoint proteins, and utilizing the synthetic lethality phenomena has led to seminal discoveries. Efforts to efficiently translate the basic findings to the clinic are currently underway. Chromatin modulation is an integral part of DNA repair cascades and an emerging field of investigation. Here, we discuss some of the key advancements made in DNA repair-based therapeutics and what is known regarding crosstalk between chromatin and repair pathways during various cellular processes, with an emphasis on cancer.

Entities:  

Keywords:  DNA repair; cancer therapy; histone deacetylases; repair inhibition

Year:  2021        PMID： 33498525      PMCID： PMC7864178          DOI： 10.3390/cancers13030381

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.575


  126 in total

Review 1.  Understanding the Histone DNA Repair Code: H4K20me2 Makes Its Mark.

Authors:  Karissa L Paquin; Niall G Howlett
Journal:  Mol Cancer Res       Date:  2018-06-01       Impact factor: 5.852

2.  MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

Authors:  Silvia Maifrede; Esteban Martinez; Margaret Nieborowska-Skorska; Daniela Di Marcantonio; Michael Hulse; Bac Viet Le; Huaqing Zhao; Katarzyna Piwocka; Italo Tempera; Stephen M Sykes; Tomasz Skorski
Journal:  Blood Adv       Date:  2017-08-09

3.  AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models.

Authors:  Sofia Ferreira; Chloe Foray; Alberto Gatto; Magalie Larcher; Sophie Heinrich; Mihaela Lupu; Joel Mispelter; François D Boussin; Célio Pouponnot; Marie Dutreix
Journal:  Clin Cancer Res       Date:  2020-09-08       Impact factor: 12.531

4.  EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

Authors:  Beatrice Rondinelli; Ewa Gogola; Hatice Yücel; Alexandra A Duarte; Marieke van de Ven; Roxanne van der Sluijs; Panagiotis A Konstantinopoulos; Jos Jonkers; Raphaël Ceccaldi; Sven Rottenberg; Alan D D'Andrea
Journal:  Nat Cell Biol       Date:  2017-10-16       Impact factor: 28.824

5.  Distinct roles of ATR and DNA-PKcs in triggering DNA damage responses in ATM-deficient cells.

Authors:  Nozomi Tomimatsu; Bipasha Mukherjee; Sandeep Burma
Journal:  EMBO Rep       Date:  2009-05-15       Impact factor: 8.807

Review 6.  Diseases associated with defective responses to DNA damage.

Authors:  Mark O'Driscoll
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-12-01       Impact factor: 10.005

Review 7.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

8.  HDAC3 is essential for DNA replication in hematopoietic progenitor cells.

Authors:  Alyssa R Summers; Melissa A Fischer; Kristy R Stengel; Yue Zhao; Jonathan F Kaiser; Christina E Wells; Aubrey Hunt; Srividya Bhaskara; Jessica W Luzwick; Shilpa Sampathi; Xi Chen; Mary Ann Thompson; David Cortez; Scott W Hiebert
Journal:  J Clin Invest       Date:  2013-06-10       Impact factor: 14.808

9.  Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.

Authors:  Timothy A Yap; Brent O'Carrigan; Marina S Penney; Joline S Lim; Jessica S Brown; Maria J de Miguel Luken; Nina Tunariu; Raquel Perez-Lopez; Daniel Nava Rodrigues; Ruth Riisnaes; Ines Figueiredo; Suzanne Carreira; Brian Hare; Katherine McDermott; Saira Khalique; Chris T Williamson; Rachael Natrajan; Stephen J Pettitt; Christopher J Lord; Udai Banerji; John Pollard; Juanita Lopez; Johann S de Bono
Journal:  J Clin Oncol       Date:  2020-06-22       Impact factor: 44.544

10.  The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.

Authors:  Vijayalakshmi Kari; Sanjay Kumar Raul; Jana Maria Henck; Julia Kitz; Frank Kramer; Robyn Laura Kosinsky; Nadine Übelmesser; Wael Yassin Mansour; Jessica Eggert; Melanie Spitzner; Zeynab Najafova; Holger Bastians; Marian Grade; Jochen Gaedcke; Florian Wegwitz; Steven A Johnsen
Journal:  Clin Epigenetics       Date:  2019-01-07       Impact factor: 6.551
View more
  3 in total

Review 1.  H2A.X Phosphorylation in Oxidative Stress and Risk Assessment in Plasma Medicine.

Authors:  Clarissa S Schütz; Matthias B Stope; Sander Bekeschus
Journal:  Oxid Med Cell Longev       Date:  2021-12-13       Impact factor: 6.543

2.  ERCC1 Overexpression Increases Radioresistance in Colorectal Cancer Cells.

Authors:  Yi-Jung Huang; Ming-Yii Huang; Tian-Lu Cheng; Shih-Hsun Kuo; Chien-Chih Ke; Yi-Ting Chen; Yuan-Chin Hsieh; Jaw-Yuan Wang; Chiu-Min Cheng; Chih-Hung Chuang
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

Review 3.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.

Authors:  Anna E Harris; Veronika M Metzler; Jennifer Lothion-Roy; Dhruvika Varun; Corinne L Woodcock; Daisy B Haigh; Chantelle Endeley; Maria Haque; Michael S Toss; Mansour Alsaleem; Jenny L Persson; Lorraine J Gudas; Emad Rakha; Brian D Robinson; Francesca Khani; Laura M Martin; Jenna E Moyer; Juliette Brownlie; Srinivasan Madhusudan; Cinzia Allegrucci; Victoria H James; Catrin S Rutland; Rupert G Fray; Atara Ntekim; Simone de Brot; Nigel P Mongan; Jennie N Jeyapalan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-10-03       Impact factor: 6.055
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.